Other than have fun with it, I see no need to respond to an

New Post Public Reply Private Reply Replies (1) Message Board
SaltyMutt Bhawks #23195
207
Other than have fun with it, I see no need to respond to an article that is nothing more than bovine squat and, if altered just a wee bit, could easily used by Repubbies to "Loon up" you Librul nut burgers. Pease allow me to show you what I mean.


Quote:
In Case You've Ever Wondered ...

By NanceGreggs
https://www.democraticunderground.com/index.php

It’s not that being a Dimmycrat turns you into someone who is easily manipulated, woefully ill-informed, and – for lack of a better term – downright stupid.

It’s that the Dimmycrat party has courted people like that for decades precisely because they’re easily manipulated, woefully ill-informed, and/or downright stupid.

The reason for enticing such voters is obvious. If you want supporters who don’t pay attention to the news, can be convinced to vote against their own best interests, and will literally believe anything you tell them, you don’t waste your time trying to find recruits among the intelligent, well-informed thinking class.

The gullible, the easily-led, those who refuse to acknowledge facts – they didn’t just wander into the Dimmycrat party. They were specifically targeted as likely marks – people who don’t have the common sense to recognize that they’ve been fucked over, time and again, by the very party they have been convinced is championing their cause.


Nope, by no means did the Greggs article flummox anyone and is nothing more than the tiniest of twigs, complete with sparrow poop, that some with a defective neuron will consider to be a massive smelly war club. LOL LOL LOL LOL LOL

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Merck & Co., Inc. Investors Urged to Take Action Now

Updated Category News Views 131

Important Notice for Merck & Co., Inc. Investors Investors in Merck & Co., Inc. (MRK) are being encouraged to seek legal counsel as we approach a significant deadline related to a securities class action lawsuit. This timeline marks an important opportunity for purchasers of Merck's securities made between February 3, 2022, and February 3, 2025, to secure representation...

Continue Reading
Justice-Impacted Individuals Gaining Access to Education

Updated Category News Views 116

Expanding Opportunities for Justice-Impacted Individuals In a significant initiative aimed at improving the lives of justice-impacted individuals, multiple states are coming together to enhance educational and workforce pathways. This collaborative effort is focused on providing necessary resources and opportunities for individuals who have faced incarceration, aiming to...

Continue Reading
Celebrating Excellence: 2025 Lifetime Achievement Award Recipients

Updated Category News Views 123

Honoring Peter Murray and SawTeen See at the CTBUH 2025 Awards The Council on Tall Buildings and Urban Habitat (CTBUH) has recognized two remarkable figures in the field of architecture and structural engineering for their essential contributions to urban design. Peter Murray, co-founder of New London Architecture, and SawTeen See, a prominent structural engineer, are the...

Continue Reading
Northern Oil and Gas Expands Horizons with Acquisition Talks

Updated Category News Views 145

Northern Oil and Gas Options for Strategic Growth Northern Oil and Gas is actively pursuing acquisition opportunities, specifically targeting Granite Ridge Resources. Based in Minneapolis, this ambitious company has shown intent to enhance its portfolio by considering Granite Ridge, a relatively smaller player in the oil industry, skilled in extracting resources from...

Continue Reading
Invivyd Announces Insights into VYD2311's Clinical Journey

Updated Category News Views 176

Invivyd Hosts Webcast to Discuss the REVOLUTION Program Invivyd, Inc. (Nasdaq: IVVD) will present a live webcast detailing its innovative REVOLUTION clinical program. This event, aimed at both investors and the public, will showcase the company’s promising monoclonal antibody, VYD2311, which serves as a vaccine alternative for COVID-19 prevention. The Overview of...

Continue Reading